Novartis AG (NVS) said Thursday that a phase 3 study of its drug Cosentyx combined with a 26-week steroid taper in adults with newly diagnosed or relapsing giant cell arteritis did not meet its primary endpoint of statistically significant improvement in sustained remission at 52 weeks compared with placebo plus a 52-week steroid taper.
While secondary outcomes also did not show statistical superiority, they showed "numerically better outcomes" compared to the placebo, the company said.
Novartis said it will complete a full evaluation of the study data and share the results later.
Giant cell arteritis is a common form of vasculitis that may cause vision loss and life-threatening aneurysms.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。